Literature DB >> 27912867

Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27912867     DOI： 10.1016/j.jcjd.2016.09.003

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN： 1499-2671            Impact factor:   4.190


× No keyword cloud information.
  16 in total

Review 1.  Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review.

Authors:  Salvatore Carbone; Dave L Dixon; Leo F Buckley; Antonio Abbate
Journal:  Mayo Clin Proc       Date:  2018-11       Impact factor: 7.616

2.  Review of the top 5 cardiology studies of 2015-16.

Authors:  Arden R Barry; Hazal E Babadagli; Jade E Basaraba; Rosaleen Boswell; June W Chen; Mohamed A Omar; Dylan M Pollmann; Jian Song Zhou; Margaret L Ackman
Journal:  Can Pharm J (Ott)       Date:  2017-09-15

3.  Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.

Authors:  Siddhartha Dutta; Tarun Kumar; Surjit Singh; Sneha Ambwani; Jaykaran Charan; Shoban B Varthya
Journal:  J Family Med Prim Care       Date:  2022-03-10

4.  Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D).

Authors:  Guntram Schernthaner; Kamlesh Khunti; Chaim Lotan; Michel Burnier; Heinz Drexel; Martin Prázný
Journal:  Ther Clin Risk Manag       Date:  2017-12-13       Impact factor: 2.423

5.  Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Authors:  William T Cefalu; Sanjay Kaul; Hertzel C Gerstein; Rury R Holman; Bernard Zinman; Jay S Skyler; Jennifer B Green; John B Buse; Silvio E Inzucchi; Lawrence A Leiter; Itamar Raz; Julio Rosenstock; Matthew C Riddle
Journal:  Diabetes Care       Date:  2018-01       Impact factor: 19.112

Review 6.  Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

Authors:  Vishal Gupta; William Canovatchel; B N Lokesh; Ravi Santani; Nishant Garodia
Journal:  Indian J Endocrinol Metab       Date:  2017 Nov-Dec

7.  Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial.

Authors:  Lawrence A Leiter; Marina V Shestakova; Ilhan Satman
Journal:  Diabetol Metab Syndr       Date:  2018-04-10       Impact factor: 3.320

8.  Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.

Authors:  Julio Rosenstock; Yehuda Handelsman; Josep Vidal; F Javier Ampudia Blasco; Francesco Giorgino; Minzhi Liu; Riccardo Perfetti; Juris J Meier
Journal:  Diabetes Obes Metab       Date:  2018-08-13       Impact factor: 6.577

Review 9.  Antihyperglycemic Medications and Cardiovascular Risk Reduction.

Authors:  Sarah L Anderson; Joel C Marrs
Journal:  Eur Endocrinol       Date:  2017-08-22

10.  Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.

Authors:  Cristiano S Moura; Zale B Rosenberg; Michal Abrahamowicz; Sasha Bernatsky; Hassan Behlouli; Louise Pilote
Journal:  J Diabetes Res       Date:  2018-03-11       Impact factor: 4.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.